Skip to main content

Table 2 Prevalence of Pfdhfr and Pfdhps mutations according to IPTp-SP groups

From: Recent uptake of intermittent preventive treatment during pregnancy with sulfadoxine–pyrimethamine is associated with increased prevalence of Pfdhfr mutations in Bobo-Dioulasso, Burkina Faso

Mutation allele

Total (N = 101)

IPTp-SP− (n = 52)

IPTp-SP+ (n = 49)

Crude OR 95% CI

P value

Pfdhfr N51I

    

0.003

 No

29 (28.7)

8 (15.4)

21 (42.9)

1

 

 Yes

72 (71.3)

44 (84.6)

28 (57.1)

0.24 (0.09–0.62)

 

Pfdhfr C59R

     

 No

58 (57.4)

37 (71.2)

21 (42.9)

1

0.005

 Yes

43 (42.6)

15 (28.9)

28 (57.1)

3.29 (1.44–7.50)

 

Pfdhfr S108N

     

 No

36 (35.6)

22 (42.3)

14 (28.6)

1

0.1

 Yes

65 (64.4)

30 (57.7)

35 (71.4)

1.83 (0.80–4.20)

 

Pfdhps A437G

     

 No

20 (19.8)

11 (21.2)

9 (18.4)

1

0.7

 Yes

81 (80.2)

41 (78.8)

40 (81.6)

1.19 (0.45–3.19)

 

Pfdhfr double mutation

    

0.7

 No

60 (59.4)

30 (57.7)

30 (61.2)

1

 

 Yes

41 (40.6)

22 (42.3)

19 (38.8)

0.86 (0.40–1.91)

 

Pfdhfr triple mutation

    

0.1

 No

75 (74.3)

42 (80.8)

33 (67.4)

1

 

 Yes

26 (25.7)

10 (19.2)

16 (32.6)

2.04 (0.82–5.07)

 

≥2 Pfdhfr mutation

    

0.3

 No

34 (33.7)

20 (38.5)

14 (28.6)

1

 

 Yes

67 (66.3)

32 (61.5)

35 (71.4)

1.56 (0.69–3.60)